IBDEI1GS ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25979,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25979,1,2,0)
 ;;=2^V62.84
 ;;^UTILITY(U,$J,358.3,25979,1,5,0)
 ;;=5^Suicidal Ideation
 ;;^UTILITY(U,$J,358.3,25979,2)
 ;;=^332876
 ;;^UTILITY(U,$J,358.3,25980,0)
 ;;=V62.85^^150^1648^18
 ;;^UTILITY(U,$J,358.3,25980,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25980,1,2,0)
 ;;=2^V62.85
 ;;^UTILITY(U,$J,358.3,25980,1,5,0)
 ;;=5^Homicidal Ideation
 ;;^UTILITY(U,$J,358.3,25980,2)
 ;;=^339690
 ;;^UTILITY(U,$J,358.3,25981,0)
 ;;=V58.61^^150^1648^25
 ;;^UTILITY(U,$J,358.3,25981,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25981,1,2,0)
 ;;=2^V58.61
 ;;^UTILITY(U,$J,358.3,25981,1,5,0)
 ;;=5^L/T (Current) Anticoagulant Use
 ;;^UTILITY(U,$J,358.3,25981,2)
 ;;=^303459
 ;;^UTILITY(U,$J,358.3,25982,0)
 ;;=V58.62^^150^1648^24
 ;;^UTILITY(U,$J,358.3,25982,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25982,1,2,0)
 ;;=2^V58.62
 ;;^UTILITY(U,$J,358.3,25982,1,5,0)
 ;;=5^L/T (Current) Antibiotics Use
 ;;^UTILITY(U,$J,358.3,25982,2)
 ;;=^321546
 ;;^UTILITY(U,$J,358.3,25983,0)
 ;;=V58.63^^150^1648^26
 ;;^UTILITY(U,$J,358.3,25983,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25983,1,2,0)
 ;;=2^V58.63
 ;;^UTILITY(U,$J,358.3,25983,1,5,0)
 ;;=5^L/T (Current) Antiplts/Antithrmbtcs
 ;;^UTILITY(U,$J,358.3,25983,2)
 ;;=^329978
 ;;^UTILITY(U,$J,358.3,25984,0)
 ;;=V58.64^^150^1648^30
 ;;^UTILITY(U,$J,358.3,25984,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25984,1,2,0)
 ;;=2^V58.64
 ;;^UTILITY(U,$J,358.3,25984,1,5,0)
 ;;=5^L/T (Current) NSAIDS Use
 ;;^UTILITY(U,$J,358.3,25984,2)
 ;;=^329979
 ;;^UTILITY(U,$J,358.3,25985,0)
 ;;=V58.65^^150^1648^32
 ;;^UTILITY(U,$J,358.3,25985,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25985,1,2,0)
 ;;=2^V58.65
 ;;^UTILITY(U,$J,358.3,25985,1,5,0)
 ;;=5^L/T (Current) Steroids Use
 ;;^UTILITY(U,$J,358.3,25985,2)
 ;;=^329980
 ;;^UTILITY(U,$J,358.3,25986,0)
 ;;=V58.66^^150^1648^27
 ;;^UTILITY(U,$J,358.3,25986,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25986,1,2,0)
 ;;=2^V58.66
 ;;^UTILITY(U,$J,358.3,25986,1,5,0)
 ;;=5^L/T (Current) Aspirin Use
 ;;^UTILITY(U,$J,358.3,25986,2)
 ;;=^331584
 ;;^UTILITY(U,$J,358.3,25987,0)
 ;;=V58.67^^150^1648^29
 ;;^UTILITY(U,$J,358.3,25987,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25987,1,2,0)
 ;;=2^V58.67
 ;;^UTILITY(U,$J,358.3,25987,1,5,0)
 ;;=5^L/T (Current) Insulin Use
 ;;^UTILITY(U,$J,358.3,25987,2)
 ;;=^331585
 ;;^UTILITY(U,$J,358.3,25988,0)
 ;;=V58.68^^150^1648^28
 ;;^UTILITY(U,$J,358.3,25988,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25988,1,2,0)
 ;;=2^V58.68
 ;;^UTILITY(U,$J,358.3,25988,1,5,0)
 ;;=5^L/T (Current) Bisphos Use
 ;;^UTILITY(U,$J,358.3,25988,2)
 ;;=^340624
 ;;^UTILITY(U,$J,358.3,25989,0)
 ;;=V58.69^^150^1648^31
 ;;^UTILITY(U,$J,358.3,25989,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25989,1,2,0)
 ;;=2^V58.69
 ;;^UTILITY(U,$J,358.3,25989,1,5,0)
 ;;=5^L/T (Current) Other Meds Use
 ;;^UTILITY(U,$J,358.3,25989,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,25990,0)
 ;;=V58.83^^150^1648^50
 ;;^UTILITY(U,$J,358.3,25990,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25990,1,2,0)
 ;;=2^V58.83
 ;;^UTILITY(U,$J,358.3,25990,1,5,0)
 ;;=5^Therapeutic Drug Monitoring
 ;;^UTILITY(U,$J,358.3,25990,2)
 ;;=^322076
 ;;^UTILITY(U,$J,358.3,25991,0)
 ;;=V62.5^^150^1648^34
 ;;^UTILITY(U,$J,358.3,25991,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25991,1,2,0)
 ;;=2^V62.5
 ;;^UTILITY(U,$J,358.3,25991,1,5,0)
 ;;=5^Legal Circumstances
 ;;^UTILITY(U,$J,358.3,25991,2)
 ;;=^175799
 ;;^UTILITY(U,$J,358.3,25992,0)
 ;;=V79.1^^150^1649^1
 ;;^UTILITY(U,$J,358.3,25992,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25992,1,2,0)
 ;;=2^V79.1
 ;;
 ;;$END ROU IBDEI1GS
